

MIMEDX GROUP, INC.  
Form 8-K  
October 22, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 19, 2009**

**MIMEDX GROUP, INC.**

(Exact name of registrant as specified in its charter)

**Florida**

(State or other Jurisdiction of  
Incorporation)

**000-52491**

(Commission File Number)

**90-0300868**

(IRS Employer Identification No.)

**811 Livingston Court, Suite B**

**Marietta, GA**

(Address of Principal Executive Offices)

**30076**

(Zip Code)

Registrant's telephone number, including area code: **(678) 384-6720**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Section 1 Registrant's Business and Operations

### Item 1.01 Entry into a Material Definitive Agreement

On October 19, 2009, the registrant's wholly-owned subsidiary, MiMedx, Inc. (the Company), entered into a Sale and Purchase Agreement (the Agreement) with UPex Holdings, LLC (UPex), a design and distribution company that focuses on upper extremity orthopedic products. A copy of the Agreement is attached hereto as Exhibit 2.1 and is incorporated herein by reference in its entirety. The transactions contemplated by the Agreement closed on October 19, 2009.

Pursuant to the Agreement, the Company sold and UPex purchased eight patent applications and the related intellectual property that comprised the Company's upper extremities business, Level Orthopedics (the Acquired Intellectual Property). The purchase price for the Acquired Intellectual Property was up to \$1,030,000, payable as follows: \$300,000 cash paid at closing, \$100,000 by the issuance at closing of a secured promissory note, and up to \$630,000 in royalty obligations.

The Secured Promissory Note is payable in monthly installments of \$5,000 plus accrued interest at the rate of 3% per annum, commencing January 1, 2010, and continuing until August 1, 2011. Payment of the note is secured by a security interest in the Acquired Intellectual Property in favor of the Company.

The Agreement also provides for monthly royalty payments equal to five percent (5%) of the gross revenue received by UPex, from any sale, license or other disposition of the Acquired Intellectual Property in the ordinary course of business or from any sale, license or other disposition of any product or device that embodies any of the Acquired Intellectual Property. Royalty payments are capped at \$630,000.

In conjunction with the Agreement, UPex assumed and agreed to perform all duties and responsibilities of the Company under the Consulting Agreement dated September 21, 2007, as amended, between the Company and Thomas J. Graham, M.D.

## Section 2 Financial Information

### Item 2.01 Completion of Acquisition or Disposition of Assets

The description in response to Item 1.01 is hereby incorporated by reference in its entirety to this item. Other than with respect to the transaction, neither the Company, nor any of its affiliates, nor any of its directors or officers nor any associate of any of its directors or officers has any material relationship with UPex.

## Section 9 Financial Statements and Exhibits

### Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Number	Description
2.1	Sale and Purchase Agreement, dated October 19, 2009, between UPex Holdings, LLC and MiMedx, Inc.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MIMEDX GROUP, INC.

October 22, 2009

By: /s/ Michael J.

Culumber

Michael J. Culumber, Chief Financial Officer

3

3

---

**EXHIBIT INDEX**

Number	Description
2.1	Sale and Purchase Agreement, dated October 19, 2009, between UPex Holdings, LLC and MiMedx, Inc.
	4
	4